Targeting galectin-1-induced angiogenesis mitigates the severity of endometriosis

Journal of Pathology

Volumn 234, Issue 3, 2014, Pages 329-337

  Bastón, Juan I ^a   Barañao, Rosa I ^a   Ricci, Analía G ^a   Bilotas, Mariela A ^a   Olivares, Carla N ^a   Singla, José J ^b   Gonzalez, Alejandro M ^c   Stupirski, Juan C ^a   Croci, Diego O ^a   Rabinovich, Gabriel A ^a   Meresman, Gabriela F ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^c Hospital Naval Pedro Mallo   (Argentina)

Author keywords

Angiogenesis; Endometriosis; Galectin 1

Indexed keywords

BINDING PROTEIN; GALECTIN 1; GALECTIN 1 MONOCLONAL ANTIBODY; KERATINOCYTE DERIVED CHEMOKINE; LECTIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIOSIS; ENDOTHELIUM CELL; FEMALE; FEMALE INFERTILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PELVIC PAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THERAPY EFFECT; WILD TYPE; ANIMAL; C57BL MOUSE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; ENDOMETRIOSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GALECTIN 1; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84907938020     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4397     Document Type: Article

References (45)

1. Bulun SE. Endometriosis. N Engl J Med 2009; 360: 268-279.
2. Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364: 1789-1799.
3. Crosignani P, Olive D, Bergqvist A, et al. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006; 12: 179-189.
4. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003; 189: 280-294.
5. Becker CM, D'Amato RJ. Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 2007; 74: 121-130.
6. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007; 13: 331-342.
7. RicciAG,Olivares CN, Bilotas MA, et al. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci 2011; 18: 614-622.
8. Varma R, Rollason T, Gupta JK, et al. Endometriosis and the neoplastic process. Reproduction 2004; 127: 293-304.
9. Kajihara H, Yamada Y, Kanayama S, et al. New insights into the pathophysiology of endometriosis: from chronic inflammation to danger signal. Gynecol Endocrinol 2011; 27: 73-79.
10. Tariverdian N, Theoharides TC, Siedentopf F, et al. Neuroendocrine-immune disequilibrium and endometriosis:an interdisciplinary approach. Semin Immunopathol 2007; 29:193-210.
11. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36: 322-335.
12. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5: 241-251.
13. Thijssen VL, Barkan B, Shoji H, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010; 70:6216-6224.
14. Croci DO, Salatino M, Rubinstein N, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012; 209:1985-2000.
15. Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylationdependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014; 156: 744-758.
16. Blois SM, Ilarregui JM, Tometten M, et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nature Med 2007; 13:1450-1457.
17. Ramhorst RE, Giribaldi L, Fraccaroli L, et al. Galectin-1 confers immune privilege to human trophoblast: implications in recurrent fetal loss. Glycobiology 2012; 22: 1374-1386.
18. Freitag N, Tirado-Gonzalez I, Barrientos G, et al. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci U S A 2013; 110: 11451-11456.
19. von Wolff M, Wang X, Gabius HJ, et al. Galectin fingerprinting in human endometrium and decidua during the menstrual cycle and in early gestation. Mol Hum Reprod 2005; 11: 189-194.
20. Choe YS, Shim C, Choi D, et al. Expression of galectin-1 mRNA in the mouse uterus is under the control of ovarian steroids during blastocyst implantation. Mol Reprod Dev 1997; 48: 261-266.
21. Meresman GF, Vighi S, Buquet RA, et al. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000; 74: 760-766.
22. Olivares CN, Bilotas MA, Ricci AG, et al. Anastrozole and celecoxib for endometriosis treatment, good to keep them apart? Reproduction 2013; 145: 119-126.
23. Bilotas M, Meresman G, Stella I, et al. Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. Fertil Steril 2010; 93: 2513-2518.
24. Ouyang J, Juszczynski P, Rodig SJ, et al. Viral induction and targeted inhibition of galectin-1 in EBV + posttransplant lymphoproliferative disorders. Blood 2011; 117: 4315-4322.
25. Eggermont J, Donnez J, Casanas-Roux F, et al. Time course of pelvic endometriotic lesion revascularization in a nude mouse model. Fertil Steril 2005; 84: 492-499.
26. Becker CM,Wright RD, Satchi-Fainaro R, et al. A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol 2006; 168: 2074-2084.
27. Olivares C, Ricci A, Bilotas M, et al. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril 2011; 96: 428-433.
28. Albrecht I, Kopfstein L, Strittmatter K, et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 2010; 5: e14109.
29. Belo AV, Leles F, Barcelos LS, et al. Murine chemokine CXCL2/KC is a surrogate marker for angiogenic activity in the inflammatory granulation tissue. Microcirculation 2005; 12: 597-606.
30. Becker CM, SampsonDA, Short SM, et al. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 2006; 85: 71-77.
31. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 2012; 18:682-702.
32. Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 2009; 24: 1025-1035.
33. Peeters LL, Vigne JL, Tee MK, et al. PPARgamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 2005; 8: 373-379.
34. Thijssen VL, Rabinovich GA, Griffioen AW. Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev 2013; 24: 547-558.
35. Hsieh SH, Ying NW, Wu MH, et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 2008; 27: 3746-3753.
36. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156: 899-909.
37. Delgado VM, Nugnes LG, Colombo LL, et al. Modulation of endothelial cell migration and angiogenesis: a novel function for the 'tandem-repeat' lectin galectin-8. FASEB J 2011; 25: 242-254.
38. Noel JC, Chapron C, Borghese B, et al. Galectin-3 is overexpressed in various forms of endometriosis. Appl Immunohistochem Mol Morphol 2011; 19: 253-257.
39. Nikzad H, Haddad KH, Kabir-Salmani M, et al. Expression of galectin-8 on human endometrium: molecular and cellular aspects. Iran J Reprod Med 2013; 11: 65-70.
40. Vercellini P, Crosignani P, Somigliana E, et al. 'Waiting for Godot':a commonsense approach to the medical treatment of endometriosis. Hum Reprod 2011; 26: 3-13.
41. Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs 2012; 21:905-919.
42. Ingrassia L, Camby I, Lefranc F, et al. Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 2006; 13:3513-3527.
43. Rabinovich GA, Cumashi A, Bianco GA, et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006; 16: 210-220.
44. Ito K, Ralph SJ. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence. Clin Exp Metastasis 2012; 29: 561-572.
45. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 2006; 103:15975-15980.